专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2007035348A3 NANOPARTICULATE ARIPIPRAZOLE FORMULATIONS 审中-公开
公开(公告)号：WO2007035348A3
公开(公告)日：2007-03-29
申请号：PCT/US2006/035634
申请日：2006-09-13
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , JENKINS, Scott
发明人： JENKINS, Scott
IPC分类号： A61K9/14 , A61K31/496
摘要： The present invention is directed to compositions and methods comprising nanoparticulate aripiprazole, or salts or derivatives thereof, having improved bioavailability, faster rates of absorption and a faster onset of therapeutic effect. The nanoparticulate aripiprazole compositions are proposed to have an average effective particle size of less than about 2000 nm, and may be useful for the treatment of diseases and disorders of the central nervous system, including mental diseases and disorders.

52. 发明申请

WO2007027273A1 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS 审中-公开
标题翻译：包含芳基 - 杂环化合物的纳米颗粒和控制释放组合物
公开(公告)号：WO2007027273A1
公开(公告)日：2007-03-08
申请号：PCT/US2006/023695
申请日：2006-06-19
申请人： ELAN PHARMA INTERNATIONAL LIMITED , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
发明人： DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/64
CPC分类号： A61K9/5078 , A61K9/145 , A61K9/146 , A61K9/4808 , A61K9/5084
摘要： The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.
摘要翻译：本发明提供一种包含齐拉西酮的组合物，其可用于治疗和预防精神分裂症和类似的精神障碍。在一个实施方案中，组合物包含包含齐拉西酮和至少一种表面稳定剂的纳米颗粒颗粒。纳米颗粒具有小于约2000nm的有效平均粒度。在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送齐拉西酮。本发明还涉及含有这些组合物的剂型，以及治疗和预防精神分裂症和类似精神障碍的方法。

53. 发明申请

WO2007008537A3 NANOPARTICULATE CLARITHROMYCIN FORMULATIONS 审中-公开
公开(公告)号：WO2007008537A3
公开(公告)日：2007-01-18
申请号：PCT/US2006/026232
申请日：2006-07-06
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , JENKINS, Scott , LIVERSIDGE, Gary
发明人： JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/51 , A61K9/14
摘要： The present invention is directed to compositions comprising nanoparticulate macrolides such as clarithromycin, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate macrolide particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of infection and related diseases.

54. 发明申请

WO2007002315A2 NANOPARTICULATE MEGESTROL FORMULATIONS 审中-公开
标题翻译：纳米微粒大豆制剂
公开(公告)号：WO2007002315A2
公开(公告)日：2007-01-04
申请号：PCT/US2006/024349
申请日：2006-06-22
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , HOVEY, Douglas , PRUITT, John , RYDE, Tuula
发明人： HOVEY, Douglas , PRUITT, John , RYDE, Tuula
CPC分类号： A61K9/145 , A61K9/146
摘要： The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
摘要翻译：本发明涉及包含甲地孕酮的纳米微粒组合物。组合物的甲地孕酮颗粒具有小于约2000nm的有效平均粒度。

55. 发明申请

WO2006138421A3 NANOPARTICULATE AZELNIDIPINE FORMULATIONS 审中-公开
公开(公告)号：WO2006138421A3
公开(公告)日：2006-12-28
申请号：PCT/US2006/023243
申请日：2006-06-14
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary, G.
发明人： JENKINS, Scott , LIVERSIDGE, Gary, G.
IPC分类号： A61K31/4427 , A61K9/14 , A61P9/12
摘要： The present invention is directed to compositions comprising a nanoparticulate azelnidipine, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate azelnidipine particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related diseases.

56. 发明申请

WO2006138214A1 NANOPARTICULATE CLOPIDOGREL AND ASPIRIN COMBINATION FORMULATIONS 审中-公开
标题翻译： NANOPARTICULATE CLOPIDOGREL和ASPIRIN组合制剂
公开(公告)号：WO2006138214A1
公开(公告)日：2006-12-28
申请号：PCT/US2006/022811
申请日：2006-06-12
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , JENKINS, Scott , LIVERSIDGE, Gary, G.
发明人： JENKINS, Scott , LIVERSIDGE, Gary, G.
IPC分类号： A61K31/4365 , A61K31/60 , A61P9/10
CPC分类号： A61K9/146 , A61K9/145 , A61K9/2077 , A61K9/5084 , A61K31/4365 , A61K31/4743 , A61K31/60 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to compositions comprising a nanoparticulate clopidogrel and aspirin combination, or salts or derivatives thereof, having improved clopidogrel bioavailability. The nanoparticulate clopidogrel particles, and optionally the nanoparticulate aspirin particles, of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of pathologies induced by platelet aggregation. The clopidogrel and aspirin particles may also be formulated as a controlled release polymeric coating or matrix drug delivery system.
摘要翻译：本发明涉及包含具有改善的氯吡格雷生物利用度的纳米颗粒氯吡格雷和阿司匹林组合或其盐或衍生物的组合物。组合物的纳米颗粒氯吡格雷颗粒和任选的纳米颗粒阿司匹林颗粒具有小于约2000nm的有效平均粒度，并且可用于预防和治疗由血小板聚集诱导的病理学。氯吡格雷和阿司匹林颗粒也可以配制成控释聚合物涂层或基质药物递送系统。

57. 发明申请

WO2006096462A1 NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES 审中-公开
标题翻译：杂环化合物衍生物的纳米颗粒组合物
公开(公告)号：WO2006096462A1
公开(公告)日：2006-09-14
申请号：PCT/US2006/007465
申请日：2006-03-02
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott
发明人： LIVERSIDGE, Gary , JENKINS, Scott
IPC分类号： A61K9/14
CPC分类号： A61K9/145 , A61K9/146 , A61K9/2018 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K9/2077
摘要： The present invention is directed to compositions comprising nanoparticulate heterocyclic amide derivative and preferably zafirlukast nanoparticles, also collectively referred to as "active ingredient," having improved solubility in water. The nanoparticles of the composition have an effective average particle size of less than about 2,000 nm, and are useful in the treatment of asthma. The invention also relates to a multiparticulate modified release composition comprising the active ingredient that in operation delivers the drug in a pulsed or bimodal manner for the treatment of asthma. The controlled release composition comprises an immediate release component and a modified release component. The immediate release component comprises a first population of heterocyclic amide derivative, and preferably zafirlukast particles, and the modified release component comprises a second population of heterocyclic amide derivative, and preferably zafirlukast nanoparticles, and a controlled release component, wherein the combination of the immediate release and modified release components in operation delivers the active ingredient in a pulsed or bimodal manner. The heterocyclic amide derivative can be released from the multiparticulate particles in an erosable, diffusion or osmotic controlled release system.
摘要翻译：本发明涉及包含纳米颗粒杂环酰胺衍生物和优选扎非司酮纳米颗粒的组合物，其也统称为“活性成分”，其具有改善的在水中的溶解度。组合物的纳米颗粒具有小于约2,000nm的有效平均粒度，并且可用于治疗哮喘。本发明还涉及一种多微粒改性释放组合物，其包含在操作中以脉冲或双峰方式递送药物以治疗哮喘的活性成分。控释组合物包含立即释放组分和改性释放组分。立即释放组分包含第一批杂环酰胺衍生物，优选扎法司他颗粒，并且改性释放组分包含第二组杂环酰胺衍生物，优选扎非司酮纳米颗粒和控释组分，其中立即释放组合并且操作中的改性释放组分以脉冲或双峰方式递送活性成分。杂环酰胺衍生物可以在可侵蚀，扩散或渗透控制释放系统中从多颗粒颗粒中释放。

58. 发明申请

WO2006091780A3 NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF 审中-公开
公开(公告)号：WO2006091780A3
公开(公告)日：2006-08-31
申请号：PCT/US2006/006535
申请日：2006-02-24
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott , LIVERSIDGE, Elaine
发明人： LIVERSIDGE, Gary , JENKINS, Scott , LIVERSIDGE, Elaine
IPC分类号： A61K9/50
摘要： Described are nanoparticulate docetaxel or analogue thereof compositions. The compositions, which comprise a nanoparticulate docetaxel or analogue thereof and at least one surface stabilizer, can be used in the treatment of cancer.

59. 发明申请

WO2006076533A1 CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ACYLANILIDE 审中-公开
标题翻译：控制释放包含ACYLANILIDE的组合物
公开(公告)号：WO2006076533A1
公开(公告)日：2006-07-20
申请号：PCT/US2006/001163
申请日：2006-01-12
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott
发明人： LIVERSIDGE, Gary , JENKINS, Scott
IPC分类号： A61K9/14 , A61K9/20 , A61K9/26
CPC分类号： A61K9/5084
摘要： The invention relates to a controlled release composition comprising acylanilide, and preferably bicalutamide, for use, in particular, in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of stage D2 metastatic carcinoma of the prostate. The controlled release composition comprises an immediate release component and a modified release component or formulation. The immediate release component comprises a first population of bicalutamide. The modified release formulation preferably comprises a second population of acylanilide bicalutamide, and a controlled release constituent. The controlled release formulation is preferably in the form of an erodable formulation, a diffusion controlled formulation or an osmotic controlled formulation. The combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or bi-modal manner.
摘要翻译：本发明涉及包含酰基苯胺，优选比卡鲁胺的控释组合物，特别是用于与促黄体生成激素释放激素（LHRH）类似物联合治疗以治疗前列腺D2期转移性癌。控释组合物包含立即释放组分和改性释放组分或制剂。立即释放组分包含比卡鲁胺的第一群体。改性释放制剂优选包含第二种酰基苯胺比卡鲁酰胺和控释组分。控制释放制剂优选为可侵蚀制剂，扩散控制制剂或渗透控制制剂的形式。在操作中即时释放和释放组分的组合以脉冲或双向方式递送活性成分。

60. 发明申请

WO2004031050A1 IMPROVED BLISTER PACKAGING 审中-公开
标题翻译：改进的吸塑包装
公开(公告)号：WO2004031050A1
公开(公告)日：2004-04-15
申请号：PCT/EP2003/010949
申请日：2003-10-02
申请人： ELAN PHARMA INTERNATIONAL LIMITED , STROPPOLO, Federico , LEPORI, Sandro , CICCARELLO, Franco , MILANI, Rita , BELLORINI, Lorenzo , MARCHINI GATTONI, Davide
发明人： STROPPOLO, Federico , LEPORI, Sandro , CICCARELLO, Franco , MILANI, Rita , BELLORINI, Lorenzo , MARCHINI GATTONI, Davide
IPC分类号： B65D75/32
CPC分类号： B65D75/5855 , B65D75/32 , B65D75/327 , B65D75/527 , B65D2575/3236 , B65D2575/3245
摘要： A packaging having a tray (12) having at least one recess to receive contents therein and an upper layer. The packaging also has a manually removable sheet (16) that is fixed in part to the upper layer of the tray and unfixed in part to the tray, the unfixed part of the sheet being in the form of a tab (20). The tab is located adjacent to one corner of the upper portion of the tray that forms the recess, whereby when the sheet is fixed to the tray it is an effective seal against moisture and light. The packaging may have a peel off layer that may be manually removed for those with limited dexterity. The tab has a graduated width for easy grasping by the patient. The tray does not need to be separated into subsections prior to removal of the contents therein.
摘要翻译：一种具有托盘（12）的包装，所述托盘具有至少一个用于容纳内容物的凹部和上层。该包装还具有手动可移除的片（16），其被部分地固定到托盘的上层并且部分地固定到托盘上，片的未固定部分是突片（20）的形式。突片位于邻近托盘上部形成凹槽的一个角处，从而当纸张固定在托盘上时，它是防止潮湿和有光的有效密封。包装可能具有剥离层，对于那些具有灵活性的人来说可以手动去除。标签具有刻度宽度，便于患者抓握。在取出内容物之前，托盘不需要分成小段。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式